ESLA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Estrella Immunopharma Inc (ESLA.O) is -2.24, compared to its 5-year average forward P/E of -0.57. For a more detailed relative valuation and DCF analysis to assess Estrella Immunopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.57

Current PE

-2.24

Overvalued PE

0.45

Undervalued PE

-1.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ESLA News & Events

Events Timeline

No data

News

8.5

01-06Businesswire

Estrella Immunopharma Closes $8 Million Financing to Advance Clinical Trials

8.5

01-06Newsfilter

Estrella Immunopharma Closes $8 Million Financing to Advance Clinical Trials

4.0

2025-08-12Benzinga

D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target

People Also Watch

Frequently Asked Questions

What is Estrella Immunopharma Inc (ESLA) stock price today?

The current price of ESLA is 1.2 USD — it has decreased -15.49 % in the last trading day.

What is Estrella Immunopharma Inc (ESLA)'s business?

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).

What is the price predicton of ESLA Stock?

Wall Street analysts forecast ESLA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESLA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Estrella Immunopharma Inc (ESLA)'s revenue for the last quarter?

Estrella Immunopharma Inc revenue for the last quarter amounts to -4.80M USD, increased 922.54 % YoY.

What is Estrella Immunopharma Inc (ESLA)'s earnings per share (EPS) for the last quarter?

Estrella Immunopharma Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for Estrella Immunopharma Inc (ESLA)'s fundamentals?

The market is revising No Change the revenue expectations for Estrella Immunopharma, Inc. (ESLA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -6.98%.

How many employees does Estrella Immunopharma Inc (ESLA). have?

Estrella Immunopharma Inc (ESLA) has 0 emplpoyees as of January 10 2026.

What is Estrella Immunopharma Inc (ESLA) market cap?

Today ESLA has the market capitalization of 50.44M USD.